{"gene":"BTLA","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":2003,"finding":"BTLA is an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs (ITIMs); crosslinking BTLA with antigen receptors induces tyrosine phosphorylation and association with SHP-1 and SHP-2, attenuating IL-2 production. BTLA-deficient T cells show increased proliferation and BTLA-deficient mice have increased antibody responses and enhanced EAE susceptibility.","method":"Co-immunoprecipitation, phosphorylation assays, BTLA-knockout mouse phenotyping, cytokine production assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 — original discovery paper with multiple orthogonal methods, replicated across subsequent studies","pmids":["12796776"],"is_preprint":false},{"year":2005,"finding":"Crystal structure of the BTLA-HVEM complex at 2.8 Å shows BTLA binds the N-terminal cysteine-rich domain 1 (CRD1) of HVEM, employing a unique binding surface compared with other CD28-like receptors; BTLA adopts an immunoglobulin I-set fold; light scattering demonstrates BTLA ectodomain is monomeric and forms a 1:1 complex with HVEM. Alanine-scanning mutagenesis of HVEM defined critical binding residues. BTLA recognizes the same HVEM surface as herpesvirus glycoprotein D (gD).","method":"X-ray crystallography (2.8 Å), light scattering analysis, alanine-scanning mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis validation, foundational structural paper","pmids":["16169851"],"is_preprint":false},{"year":2006,"finding":"BTLA cytoplasmic domain contains a third conserved tyrosine motif resembling a Grb-2 recruitment site; phosphopeptide pulldown with mass spectrometry identified Grb-2 and the p85 subunit of PI3K as interacting proteins. Grb-2 binds directly to the phosphotyrosine-containing peptide, whereas p85 recruitment is indirect via its association with Grb-2.","method":"Phosphotyrosine peptide pulldown, mass spectrometry, direct binding assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro peptide pulldown with MS identification; single lab, mechanistically defined","pmids":["16725108"],"is_preprint":false},{"year":2006,"finding":"Human BTLA is constitutively expressed on most CD4+ and CD8+ T cells and its expression progressively decreases upon T cell activation. Cross-linking BTLA with an agonistic mAb inhibits T cell proliferation and cytokine (IFN-γ and IL-10) production in response to anti-CD3 stimulation, demonstrating a constitutive inhibitory function.","method":"Monoclonal antibody cross-linking, T cell proliferation assays, cytokine production assays, flow cytometry","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — functional loss/gain with defined cellular phenotype, single lab","pmids":["16643847"],"is_preprint":false},{"year":2009,"finding":"BTLA interacts with HVEM in cis on the surface of naive T cells, forming a heterodimeric complex that inhibits HVEM-dependent NF-κB activation. The BTLA ectodomain acts as a competitive inhibitor, blocking BTLA and CD160 from binding HVEM in trans and initiating NF-κB activation. LIGHT can bind within the cis-complex but NF-κB activation is attenuated, suggesting BTLA prevents HVEM oligomerization.","method":"Cell surface binding assays, NF-κB reporter assays, genetic deletion of BTLA, pharmacologic disruption of cis-complex, T cell reporter systems","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (reporter assays, genetic deletion, pharmacologic disruption), replicated by later study (PMID:36081508)","pmids":["19915044"],"is_preprint":false},{"year":2008,"finding":"The HVEM-BTLA inhibitory pathway counter-regulates lymphotoxin receptor (LTβR) signaling to achieve dendritic cell homeostasis. HVEM- and BTLA-deficient mice show overpopulation of CD8α- DC subsets with a growth advantage in competitive bone marrow chimeras. DC expression of both HVEM and BTLA, as well as LTβR, is required for homeostasis.","method":"Competitive bone marrow chimeras, knockout mouse analysis, flow cytometry of DC subsets, agonist antibody treatment","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — competitive reconstitution and genetic evidence with defined cellular phenotype","pmids":["18097025"],"is_preprint":false},{"year":2008,"finding":"In a T cell transfer colitis model, HVEM on radioresistant (non-T) cells in recipient mice interacts with BTLA to prevent intestinal inflammation, demonstrating that HVEM expressed by innate immune cells exerts anti-inflammatory effects through BTLA-mediated coinhibitory signaling.","method":"Adoptive T cell transfer colitis model, bone marrow chimeras, HVEM/BTLA knockout recipients","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis via bone marrow chimeras, clean KO with defined phenotype","pmids":["18519647"],"is_preprint":false},{"year":2011,"finding":"In GVHD, BTLA serves dual roles: (1) as a receptor that delivers inhibitory signals inhibiting donor anti-host T cell responses when stimulated by an agonistic anti-BTLA antibody, and (2) as a ligand that activates HVEM pro-survival signaling in donor T cells independently of its intracellular signaling domain, as shown by a BTLA cytoplasmic-truncation mutant restoring survival of BTLA-deficient T cells.","method":"Agonistic anti-BTLA antibody, BTLA intracellular domain-deletion mutant, GVHD mouse model, survival assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — mutagenesis of signaling domain combined with in vivo disease model establishes bidirectional mechanism","pmids":["21220749"],"is_preprint":false},{"year":2013,"finding":"BTLA expression on CD8α+ dendritic cells functions as a trans-activating ligand delivering positive co-signals through HVEM expressed on CD8+ T cells, promoting effector CD8 T cell survival and memory formation in vaccinia virus infection. Mixed adoptive transfer experiments demonstrate the cell-type requirement.","method":"Mixed adoptive transfer, HVEM/BTLA knockout mouse models, viral infection model, memory T cell quantification","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with mixed adoptive transfer, two independent PMID studies converging on same mechanism","pmids":["24205056","24205057"],"is_preprint":false},{"year":2013,"finding":"In γδ T cells, BTLA expression is regulated by the transcription factor RORγt (which represses Btla transcription via its AF-2 domain) and IL-7 (which increases BTLA surface levels). BTLA limits γδ T cell numbers by restricting IL-7-responsiveness and negatively regulates IL-17 and TNF production in CD27- γδ T cells.","method":"BTLA-deficient mice, RORγt AF-2 domain mutants, IL-7 stimulation assays, dermatitis mouse model, BTLA agonism","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — genetic tools and domain mutants with in vivo phenotype readout","pmids":["24315996"],"is_preprint":false},{"year":2016,"finding":"BTLA+DEC205+CD8+CD11c+ dendritic cells efficiently induce extrathymic regulatory T (Treg) cell differentiation. Engagement of HVEM on T cells by BTLA on DCs promotes Foxp3 expression via upregulation of CD5, which enables T cells to resist inhibition of Foxp3 by effector-differentiating cytokines.","method":"DC subset purification and T cell co-culture, BTLA/HVEM knockout mice, Foxp3 and CD5 expression analysis, in vivo tolerance models","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — mechanistic pathway dissection with genetic tools and defined molecular intermediates","pmids":["27793593"],"is_preprint":false},{"year":2018,"finding":"BTLA function is impaired in lupus CD4+ T cells due to defective recruitment of BTLA to the immunological synapse following T cell stimulation; this defect can be corrected by restoring intracellular lipid metabolism and trafficking in SLE T cells.","method":"Immunological synapse imaging, BTLA localization assays, lipid metabolism rescue experiments, functional T cell assays","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiment tied to functional consequence, single lab","pmids":["29997289"],"is_preprint":false},{"year":2019,"finding":"Quantitative interactomics in primary T cells shows BTLA predominantly recruits SHP-1 (and to a lesser extent SHP-2) to form its coinhibitory signalosome, in contrast to PD-1 which predominantly recruits SHP-2. Both BTLA-SHP-1 and PD-1-SHP-2 complexes equally dampen TCR and CD28 signaling pathways.","method":"Quantitative mass spectrometry interactomics (AP-MS) in primary T cells, T cell-APC interface analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 — quantitative interactomics in primary cells with rigorous controls, confirmed by independent study","pmids":["31189114"],"is_preprint":false},{"year":2019,"finding":"BTLA signaling into T cells through SHP1 reduces TCR signaling and preformed CD40 ligand mobilization to the immunological synapse, diminishing T cell help delivered to germinal center B cells. T cell-specific BTLA deficiency cooperates with B cell Bcl-2 overexpression to drive GC B cell outgrowth, establishing BTLA as a cell-extrinsic suppressor of GC B cell lymphomagenesis.","method":"BTLA conditional knockout mice, immunological synapse imaging, TCR signaling assays, CD40L mobilization assays, GC response analysis, Bcl-2 transgenic cooperation","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods linking molecular mechanism to in vivo disease phenotype","pmids":["31204070"],"is_preprint":false},{"year":2020,"finding":"BTLA preferentially recruits SHP-1 over SHP-2 to suppress T cell signaling more efficiently than PD-1. In SHP1/SHP2 double-deficient primary T cells, both PD-1 and BTLA still potently inhibit proliferation and cytokine production, demonstrating that both receptors can also suppress T cell signaling through a mechanism independent of SHP1 and SHP2.","method":"SHP1/SHP2 double-deficient primary T cells, reconstitution assays, T cell proliferation and cytokine assays, phosphatase recruitment comparison","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1-2 — genetic double-knockout combined with functional assays, two independent groups reaching similar conclusions","pmids":["32437509"],"is_preprint":false},{"year":2021,"finding":"Crystal structures reveal HVEM simultaneously interacts with LIGHT via one surface and with BTLA/CD160 via the distinct CRD1 surface, forming a ternary complex. Mouse HVEM knockin mutants selectively recognizing either TNF or Ig ligands demonstrate selective in vivo functions: LIGHT drives clearance of intestinal bacteria, while Ig ligands (BTLA/CD160) ameliorate liver inflammation.","method":"X-ray crystallography (human HVEM-LIGHT-CD160 ternary complex), site-directed mutagenesis, knockin mouse models, in vivo infection and inflammation models","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus knockin mutagenesis in vivo, rigorous functional dissection","pmids":["34709351"],"is_preprint":false},{"year":2022,"finding":"In the BTLA-HVEM cis-complex on T cells, BTLA-mediated inhibition is not impaired; co-expression with LIGHT or CD160 (but not BTLA) induces strong constitutive HVEM signaling. BTLA inhibition is dominant in the heterodimeric cis-complex, and HVEM antibodies can simultaneously act as checkpoint inhibitors and costimulation agonists.","method":"T cell reporter systems, primary human T cell stimulation assays, co-expression studies with HVEM ligands","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 — reporter systems plus primary T cells, single lab","pmids":["36081508"],"is_preprint":false},{"year":2024,"finding":"BTLA inhibits CAR T cells via recruitment of tyrosine phosphatases SHP-1 and SHP-2 upon trans engagement with HVEM on regulatory T cells in the tumor microenvironment. Deletion of BTLA in CAR T cells improves tumor control and persistence in lymphoma and solid tumor models.","method":"BTLA knockout CAR T cells, phosphatase recruitment assays, mouse lymphoma and solid tumor models, CAR T cell functional assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic deletion with defined molecular mechanism and in vivo tumor models","pmids":["38831106"],"is_preprint":false},{"year":2024,"finding":"BTLA levels are upregulated on CD4+ T cells from HBV-ACLF patients by IL-6 and TNF signaling pathways. Antibody crosslinking of BTLA activates the PI3K-Akt pathway to inhibit activation, proliferation, and cytokine production of CD4+ T cells while promoting apoptosis. BTLA knockdown promotes CD4+ T cell activation and proliferation. BTLA-/- ACLF mice show increased cytokine secretion and reduced mortality and bacterial burden.","method":"BTLA antibody crosslinking, PI3K-Akt pathway activation assays, BTLA knockdown, BTLA-knockout ACLF mouse model, anti-BTLA neutralizing antibody treatment","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (antibody crosslinking, knockdown, knockout mice) with defined molecular pathway","pmids":["38418488"],"is_preprint":false},{"year":2017,"finding":"The Grb2-binding motif of BTLA mediates a costimulatory function in CD8+ T cells by enhancing IL-2 secretion and Src activation after TCR stimulation. BTLA+ CD8+ TILs show improved survival following tumor target killing and enhanced serial killing capacity; BTLA- TILs have impaired recall responses to vaccination.","method":"BTLA signaling motif mutants (ITIM/ITSM vs Grb2 motif), RPPA signaling arrays, antigen-specific vaccination models, adoptive transfer with TCR-transgenic T cells, PDX tumor models","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — domain mutagenesis with multiple functional readouts, single lab","pmids":["28754817"],"is_preprint":false},{"year":2012,"finding":"BTLA expression in macrophages promotes the pathogenesis of virus-induced fulminant hepatitis by enhancing macrophage viability. BTLA-/- mice show rapid TRAIL-dependent apoptosis of MHV-3-infected macrophages, resulting in reduced TNFα, FGL2, viral titers, and improved survival. Adoptive transfer of macrophages to BTLA-/- mice restores sensitivity.","method":"BTLA-knockout mouse model, MHV-3 infection, macrophage adoptive transfer, BTLA blockade, TRAIL-dependent apoptosis assays, cytokine measurements","journal":"Gut","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with mechanistic rescue via adoptive transfer, multiple orthogonal validations","pmids":["22637698"],"is_preprint":false},{"year":2012,"finding":"BTLA interaction with HVEM inhibits CpG (TLR9)-mediated B cell functions including proliferation, cytokine production, and upregulation of co-stimulatory molecules; this inhibition is reversed by blocking BTLA/HVEM interactions. Chemokine secretion (IL-8 and MIP1β) is not affected, showing BTLA-mediated inhibition is selective for certain B cell functions.","method":"CpG stimulation of human B cells, BTLA/HVEM blocking antibodies, functional assays for proliferation and cytokine production","journal":"Journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — functional blocking with defined selectivity, single lab","pmids":["22903545"],"is_preprint":false}],"current_model":"BTLA is an ITIM-containing immunoglobulin superfamily inhibitory receptor that, upon tyrosine phosphorylation triggered by antigen receptor crosslinking or HVEM engagement in trans, recruits predominantly SHP-1 (and to a lesser extent SHP-2) to suppress TCR/CD28 and BCR signaling, inhibit IL-2 production, and restrain T and B cell proliferation; BTLA also forms a cis-heterodimeric complex with its ligand HVEM on naive T cells that blocks HVEM costimulation and maintains T cell quiescence, while BTLA itself can act as a trans-activating ligand for HVEM on adjacent cells to deliver NF-κB-dependent pro-survival and memory-promoting signals, and its Grb2-binding motif additionally mediates a costimulatory function enhancing IL-2 and Src activation in CD8+ T cells."},"narrative":{"teleology":[{"year":2003,"claim":"Identification of BTLA as a novel ITIM-bearing inhibitory receptor resolved the question of whether additional immunoglobulin-family coinhibitory molecules beyond CTLA-4 and PD-1 existed, establishing that BTLA recruits SHP-1 and SHP-2 upon phosphorylation to attenuate T cell activation and antibody responses.","evidence":"BTLA-knockout mice, co-immunoprecipitation, IL-2 production assays, EAE susceptibility model","pmids":["12796776"],"confidence":"High","gaps":["Ligand for BTLA unknown at this stage","Relative contribution of SHP-1 vs SHP-2 not resolved","Mechanism of action in B cells not directly tested"]},{"year":2005,"claim":"Structural determination of the BTLA–HVEM complex revealed that an Ig-superfamily receptor binds a TNF receptor superfamily member — an unprecedented cross-family interaction — establishing the molecular basis for BTLA engagement and showing BTLA binds CRD1 of HVEM as a 1:1 monomer.","evidence":"X-ray crystallography at 2.8 Å, light scattering, alanine-scanning mutagenesis of HVEM","pmids":["16169851"],"confidence":"High","gaps":["Whether BTLA and LIGHT can simultaneously engage HVEM not resolved","In vivo significance of identified contact residues untested"]},{"year":2006,"claim":"Discovery of a Grb2-binding tyrosine motif in BTLA's cytoplasmic tail, beyond the canonical ITIMs, revealed an unexpected signaling complexity suggesting BTLA could transmit both inhibitory and costimulatory signals depending on context.","evidence":"Phosphopeptide pulldown with mass spectrometry, direct binding assays identifying Grb2 and indirect PI3K p85 recruitment","pmids":["16725108"],"confidence":"Medium","gaps":["Functional consequence of Grb2 recruitment in T cells not yet demonstrated","Whether Grb2 motif operates independently of ITIMs unclear"]},{"year":2008,"claim":"In vivo studies using bone marrow chimeras and adoptive transfer colitis models established that the BTLA–HVEM axis operates bidirectionally in distinct immune compartments — restraining T cell-mediated intestinal inflammation and controlling dendritic cell homeostasis by counter-regulating LTβR signaling.","evidence":"Competitive bone marrow chimeras, HVEM/BTLA-knockout recipients, adoptive T cell transfer colitis model","pmids":["18097025","18519647"],"confidence":"High","gaps":["Molecular mechanism linking BTLA to LTβR counter-regulation in DCs not defined","Whether BTLA acts as receptor or ligand on DCs in homeostasis unclear"]},{"year":2009,"claim":"Discovery of the BTLA–HVEM cis-complex on naive T cells revealed a cell-autonomous mechanism by which BTLA blocks HVEM costimulation and maintains T cell quiescence, answering how HVEM can be silenced despite constitutive expression on resting cells.","evidence":"Cell surface binding assays, NF-κB reporter systems, genetic deletion of BTLA, pharmacologic disruption","pmids":["19915044"],"confidence":"High","gaps":["How the cis-complex is disrupted during activation not fully resolved","Whether cis-complex affects BTLA's own inhibitory signaling unknown"]},{"year":2011,"claim":"Using a BTLA cytoplasmic-truncation mutant in GVHD, BTLA was shown to function as a trans-activating ligand for HVEM independently of its own intracellular signaling, establishing a bidirectional signaling paradigm in which BTLA delivers pro-survival signals to adjacent HVEM-expressing T cells.","evidence":"BTLA intracellular domain-deletion mutant, agonistic anti-BTLA antibody, GVHD mouse model","pmids":["21220749"],"confidence":"High","gaps":["Whether ligand function requires specific BTLA ectodomain residues not mapped","Downstream NF-κB-dependent targets in HVEM-expressing cells not defined"]},{"year":2012,"claim":"BTLA's functional scope was extended beyond lymphocytes: in macrophages BTLA promotes survival during viral hepatitis (its absence causes TRAIL-dependent apoptosis), and in B cells BTLA–HVEM interaction selectively inhibits TLR9-driven proliferation and cytokine production without affecting chemokine secretion.","evidence":"BTLA-KO mice with MHV-3 infection and macrophage adoptive transfer; CpG-stimulated human B cells with BTLA/HVEM blocking antibodies","pmids":["22637698","22903545"],"confidence":"High","gaps":["How BTLA selectively inhibits certain TLR9-driven outputs but not others is unknown","Whether BTLA pro-survival signaling in macrophages is SHP-dependent or HVEM-dependent unclear"]},{"year":2013,"claim":"Mechanistic studies revealed that BTLA on CD8α+ DCs serves as a trans-ligand for HVEM on CD8+ T cells to promote effector survival and memory formation, and that RORγt transcriptionally represses Btla to license γδ T cell expansion and IL-17 production, establishing BTLA as a transcriptionally regulated checkpoint in innate-like lymphocytes.","evidence":"Mixed adoptive transfer with HVEM/BTLA-KO mice in vaccinia infection; RORγt AF-2 domain mutants, BTLA-deficient γδ T cell analysis in dermatitis model","pmids":["24205056","24205057","24315996"],"confidence":"High","gaps":["Whether BTLA ligand function on DCs requires phosphorylation of BTLA not tested","How RORγt AF-2 domain mediates Btla repression at the chromatin level undefined"]},{"year":2016,"claim":"The trans-ligand function of BTLA on DCs was linked to extrathymic Treg differentiation: BTLA engagement of HVEM on T cells upregulates CD5, which protects Foxp3 induction from suppression by effector-differentiating cytokines, placing BTLA at the nexus of peripheral tolerance.","evidence":"DC subset purification and T cell co-culture, BTLA/HVEM-KO mice, Foxp3 and CD5 expression analysis, in vivo tolerance models","pmids":["27793593"],"confidence":"High","gaps":["Signaling intermediates between HVEM engagement and CD5 upregulation not identified","Whether this mechanism operates in human Treg induction untested"]},{"year":2017,"claim":"The Grb2-binding motif of BTLA was functionally dissected in CD8+ T cells, revealing it delivers a costimulatory signal that enhances IL-2 secretion and Src activation, with BTLA+ TILs showing improved serial killing capacity — resolving how the same receptor can provide both inhibitory and costimulatory inputs.","evidence":"BTLA signaling motif mutants (ITIM/ITSM vs Grb2), RPPA signaling arrays, antigen-specific vaccination models, PDX tumor models","pmids":["28754817"],"confidence":"Medium","gaps":["How Grb2-motif costimulation integrates with ITIM-mediated inhibition in the same cell is not quantitatively modeled","Whether the costimulatory function is relevant in CD4+ T cells or other lineages unknown"]},{"year":2019,"claim":"Quantitative interactomics in primary T cells definitively established SHP-1 as the dominant BTLA phosphatase partner (distinguishing it from PD-1's SHP-2 preference), and conditional BTLA deletion in T cells showed that BTLA suppresses CD40L delivery to the immunological synapse, restraining germinal center B cell expansion and lymphomagenesis.","evidence":"AP-MS interactomics in primary T cells; conditional KO mice with Bcl-2 transgenic cooperation, immunological synapse imaging","pmids":["31189114","31204070"],"confidence":"High","gaps":["Whether SHP-1 and SHP-2 have non-redundant substrates downstream of BTLA not resolved","The SHP-independent inhibitory mechanism remains molecularly undefined"]},{"year":2020,"claim":"Generation of SHP-1/SHP-2 double-deficient T cells revealed that BTLA retains potent inhibitory function even without both phosphatases, proving the existence of a SHP-independent signaling arm whose molecular basis remains unknown.","evidence":"SHP1/SHP2 double-deficient primary T cells, reconstitution assays, proliferation and cytokine assays","pmids":["32437509"],"confidence":"High","gaps":["Identity of the SHP-independent effector(s) is unknown","Whether this mechanism operates in non-T cells not addressed"]},{"year":2021,"claim":"Crystal structures of the ternary HVEM–LIGHT–CD160/BTLA complex showed that HVEM can simultaneously engage TNF-family and Ig-family ligands on distinct surfaces, and knockin mouse mutants selectively disrupting each interface demonstrated that Ig ligands (BTLA/CD160) specifically ameliorate liver inflammation while LIGHT controls bacterial clearance.","evidence":"X-ray crystallography of human ternary complex, site-directed mutagenesis, HVEM knockin mouse models, in vivo infection and inflammation","pmids":["34709351"],"confidence":"High","gaps":["Whether BTLA and CD160 have non-redundant roles in the Ig-ligand arm not separated","Structural basis for how the cis-complex is regulated during T cell activation unclear"]},{"year":2022,"claim":"Reporter and primary T cell assays clarified that within the cis-complex, BTLA's inhibitory function remains fully active and dominant, while HVEM costimulatory signaling is specifically induced by CD160 or LIGHT but not BTLA in cis, resolving how cis and trans signaling modes are segregated.","evidence":"T cell reporter systems, primary human T cell stimulation, co-expression studies with HVEM ligands","pmids":["36081508"],"confidence":"Medium","gaps":["How BTLA cis-inhibition is overridden during strong activation signals unknown","Translation to in vivo settings not yet demonstrated"]},{"year":2024,"claim":"Translational studies demonstrated that BTLA-mediated inhibition is a functional checkpoint in CAR T cell therapy (where HVEM on Tregs engages BTLA to suppress anti-tumor activity) and in hepatitis-associated acute-on-chronic liver failure (where IL-6/TNF upregulate BTLA on CD4+ T cells to activate PI3K-Akt-mediated suppression), establishing BTLA as a therapeutic target in both cancer and inflammatory liver disease.","evidence":"BTLA-KO CAR T cells in lymphoma/solid tumor models; BTLA crosslinking with PI3K-Akt pathway analysis, BTLA-KO ACLF mouse model","pmids":["38831106","38418488"],"confidence":"High","gaps":["Whether BTLA deletion in CAR T cells affects long-term persistence and exhaustion not fully assessed","The PI3K-Akt pathway activation by BTLA crosslinking in hepatitis appears paradoxical relative to its inhibitory function and requires mechanistic clarification"]},{"year":null,"claim":"The molecular identity of the SHP-1/SHP-2-independent inhibitory effector downstream of BTLA remains unknown, and how the Grb2-mediated costimulatory and ITIM-mediated inhibitory signals are integrated within the same cell to determine net signaling outcome is unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["SHP-independent effector unidentified","Quantitative model of costimulatory vs inhibitory signal integration lacking","Structural basis for cis-to-trans complex transition during T cell activation undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,12,14,17]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,2,12]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,3,4,11]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,3,6,9,13,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,7,10,18]}],"complexes":["BTLA-HVEM cis-complex","BTLA-SHP-1 signalosome"],"partners":["TNFRSF14","PTPN6","PTPN11","GRB2","CD160","TNFSF14"],"other_free_text":[]},"mechanistic_narrative":"BTLA is an immunoglobulin superfamily coinhibitory receptor that functions as a central regulator of adaptive and innate immune cell activation, restraining T cell, B cell, dendritic cell, and macrophage responses through both receptor-intrinsic inhibitory signaling and bidirectional communication with its ligand HVEM. Upon engagement by HVEM in trans or crosslinking with the antigen receptor, BTLA undergoes tyrosine phosphorylation at its ITIM/ITSM motifs and preferentially recruits the phosphatase SHP-1 (and to a lesser extent SHP-2) to suppress TCR, CD28, and BCR signaling, thereby inhibiting proliferation, cytokine production, and CD40L mobilization to the immunological synapse [PMID:12796776, PMID:31189114, PMID:31204070]; an additional SHP-1/SHP-2-independent inhibitory mechanism also operates [PMID:32437509]. BTLA simultaneously acts as a ligand for HVEM: on naive T cells it forms a cis-heterodimeric complex with HVEM that blocks HVEM costimulation and maintains quiescence [PMID:19915044, PMID:36081508], while in trans BTLA on dendritic cells delivers NF-κB-dependent pro-survival signals through HVEM on T cells, promoting regulatory T cell differentiation, effector CD8+ T cell memory, and CD5-dependent Foxp3 induction [PMID:24205056, PMID:27793593, PMID:21220749]. A third tyrosine motif in the BTLA cytoplasmic tail recruits Grb2 and mediates a costimulatory function in CD8+ T cells that enhances IL-2 production and Src activation [PMID:16725108, PMID:28754817]."},"prefetch_data":{"uniprot":{"accession":"Q7Z6A9","full_name":"B- and T-lymphocyte attenuator","aliases":["B- and T-lymphocyte-associated protein"],"length_aa":289,"mass_kda":32.8,"function":"Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:12796776, PubMed:14652006, PubMed:15568026, PubMed:18193050). May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14 (PubMed:19915044). In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells (PubMed:19915044)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q7Z6A9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BTLA","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BTLA","total_profiled":1310},"omim":[{"mim_id":"608162","title":"V-SET DOMAIN-CONTAINING T-CELL ACTIVATION INHIBITOR 1; VTCN1","url":"https://www.omim.org/entry/608162"},{"mim_id":"607925","title":"B- AND T-LYMPHOCYTE ATTENUATOR; BTLA","url":"https://www.omim.org/entry/607925"},{"mim_id":"602746","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14; TNFRSF14","url":"https://www.omim.org/entry/602746"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":26.8}],"url":"https://www.proteinatlas.org/search/BTLA"},"hgnc":{"alias_symbol":["BTLA1","CD272"],"prev_symbol":[]},"alphafold":{"accession":"Q7Z6A9","domains":[{"cath_id":"2.60.40.10","chopping":"38-135","consensus_level":"high","plddt":94.4921,"start":38,"end":135}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q7Z6A9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q7Z6A9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q7Z6A9-F1-predicted_aligned_error_v6.png","plddt_mean":67.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BTLA","jax_strain_url":"https://www.jax.org/strain/search?query=BTLA"},"sequence":{"accession":"Q7Z6A9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q7Z6A9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q7Z6A9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q7Z6A9"}},"corpus_meta":[{"pmid":"12796776","id":"PMC_12796776","title":"BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.","date":"2003","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12796776","citation_count":691,"is_preprint":false},{"pmid":"22205715","id":"PMC_22205715","title":"CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22205715","citation_count":302,"is_preprint":false},{"pmid":"16932752","id":"PMC_16932752","title":"Balancing co-stimulation and inhibition with BTLA and HVEM.","date":"2006","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16932752","citation_count":258,"is_preprint":false},{"pmid":"19426226","id":"PMC_19426226","title":"The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19426226","citation_count":247,"is_preprint":false},{"pmid":"20307212","id":"PMC_20307212","title":"Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.","date":"2010","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20307212","citation_count":187,"is_preprint":false},{"pmid":"16169851","id":"PMC_16169851","title":"Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16169851","citation_count":140,"is_preprint":false},{"pmid":"20007250","id":"PMC_20007250","title":"HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.","date":"2009","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/20007250","citation_count":133,"is_preprint":false},{"pmid":"19915044","id":"PMC_19915044","title":"T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19915044","citation_count":131,"is_preprint":false},{"pmid":"31189114","id":"PMC_31189114","title":"Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31189114","citation_count":128,"is_preprint":false},{"pmid":"33859648","id":"PMC_33859648","title":"Roles of BTLA in Immunity and Immune Disorders.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33859648","citation_count":126,"is_preprint":false},{"pmid":"27793593","id":"PMC_27793593","title":"Immunomodulatory Functions of BTLA and HVEM Govern Induction of Extrathymic Regulatory T Cells and Tolerance by Dendritic Cells.","date":"2016","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27793593","citation_count":121,"is_preprint":false},{"pmid":"18519647","id":"PMC_18519647","title":"A crucial role for HVEM and BTLA in preventing intestinal inflammation.","date":"2008","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18519647","citation_count":115,"is_preprint":false},{"pmid":"32437509","id":"PMC_32437509","title":"PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2.","date":"2020","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32437509","citation_count":96,"is_preprint":false},{"pmid":"21106644","id":"PMC_21106644","title":"Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling.","date":"2010","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/21106644","citation_count":92,"is_preprint":false},{"pmid":"31204070","id":"PMC_31204070","title":"The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis.","date":"2019","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/31204070","citation_count":88,"is_preprint":false},{"pmid":"22459947","id":"PMC_22459947","title":"BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction.","date":"2012","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/22459947","citation_count":86,"is_preprint":false},{"pmid":"23692853","id":"PMC_23692853","title":"The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells.","date":"2013","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23692853","citation_count":82,"is_preprint":false},{"pmid":"31753019","id":"PMC_31753019","title":"BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes.","date":"2019","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31753019","citation_count":81,"is_preprint":false},{"pmid":"16643847","id":"PMC_16643847","title":"Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16643847","citation_count":79,"is_preprint":false},{"pmid":"14552835","id":"PMC_14552835","title":"BTLA: a new inhibitory receptor with a B7-like ligand.","date":"2003","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14552835","citation_count":78,"is_preprint":false},{"pmid":"18097025","id":"PMC_18097025","title":"The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18097025","citation_count":77,"is_preprint":false},{"pmid":"24315996","id":"PMC_24315996","title":"The inhibitory receptor BTLA controls γδ T cell homeostasis and inflammatory responses.","date":"2013","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/24315996","citation_count":74,"is_preprint":false},{"pmid":"22934265","id":"PMC_22934265","title":"PD-1 and BTLA and CD8(+) T-cell \"exhaustion\" in cancer: \"Exercising\" an alternative viewpoint.","date":"2012","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/22934265","citation_count":71,"is_preprint":false},{"pmid":"30984188","id":"PMC_30984188","title":"BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30984188","citation_count":70,"is_preprint":false},{"pmid":"37649037","id":"PMC_37649037","title":"Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.","date":"2023","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37649037","citation_count":69,"is_preprint":false},{"pmid":"16725108","id":"PMC_16725108","title":"Association of Grb-2 and PI3K p85 with phosphotyrosile peptides derived from BTLA.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16725108","citation_count":68,"is_preprint":false},{"pmid":"23439006","id":"PMC_23439006","title":"Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity.","date":"2013","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/23439006","citation_count":60,"is_preprint":false},{"pmid":"28754817","id":"PMC_28754817","title":"Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28754817","citation_count":60,"is_preprint":false},{"pmid":"21078889","id":"PMC_21078889","title":"Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression.","date":"2010","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21078889","citation_count":58,"is_preprint":false},{"pmid":"20038807","id":"PMC_20038807","title":"Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.","date":"2009","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20038807","citation_count":57,"is_preprint":false},{"pmid":"15922943","id":"PMC_15922943","title":"The evolving crosstalk between co-stimulatory and co-inhibitory receptors: HVEM-BTLA.","date":"2005","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15922943","citation_count":56,"is_preprint":false},{"pmid":"34532285","id":"PMC_34532285","title":"BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34532285","citation_count":55,"is_preprint":false},{"pmid":"26405566","id":"PMC_26405566","title":"BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties.","date":"2015","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/26405566","citation_count":54,"is_preprint":false},{"pmid":"26395180","id":"PMC_26395180","title":"Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer.","date":"2015","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/26395180","citation_count":53,"is_preprint":false},{"pmid":"28882621","id":"PMC_28882621","title":"Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade.","date":"2017","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/28882621","citation_count":52,"is_preprint":false},{"pmid":"32021268","id":"PMC_32021268","title":"BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32021268","citation_count":52,"is_preprint":false},{"pmid":"24205056","id":"PMC_24205056","title":"CD8 T cell memory to a viral pathogen requires trans cosignaling between HVEM and BTLA.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24205056","citation_count":50,"is_preprint":false},{"pmid":"17983390","id":"PMC_17983390","title":"Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA4Ig facilitates tolerance in murine islet allografts.","date":"2007","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/17983390","citation_count":48,"is_preprint":false},{"pmid":"24205057","id":"PMC_24205057","title":"BTLA interaction with HVEM expressed on CD8(+) T cells promotes survival and memory generation in response to a bacterial infection.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24205057","citation_count":48,"is_preprint":false},{"pmid":"21220749","id":"PMC_21220749","title":"Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21220749","citation_count":44,"is_preprint":false},{"pmid":"28123898","id":"PMC_28123898","title":"BTLA identifies dysfunctional PD-1-expressing CD4+ T cells in human hepatocellular carcinoma.","date":"2016","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/28123898","citation_count":42,"is_preprint":false},{"pmid":"34484870","id":"PMC_34484870","title":"Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma.","date":"2021","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/34484870","citation_count":41,"is_preprint":false},{"pmid":"33917094","id":"PMC_33917094","title":"BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33917094","citation_count":40,"is_preprint":false},{"pmid":"17145304","id":"PMC_17145304","title":"BTLA and HVEM cross talk regulates inhibition and costimulation.","date":"2006","source":"Advances in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17145304","citation_count":39,"is_preprint":false},{"pmid":"19585237","id":"PMC_19585237","title":"Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang Province.","date":"2009","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/19585237","citation_count":39,"is_preprint":false},{"pmid":"30116751","id":"PMC_30116751","title":"Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients.","date":"2018","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30116751","citation_count":38,"is_preprint":false},{"pmid":"27412504","id":"PMC_27412504","title":"B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27412504","citation_count":37,"is_preprint":false},{"pmid":"17024343","id":"PMC_17024343","title":"Association of a BTLA gene polymorphism with the risk of rheumatoid arthritis.","date":"2006","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/17024343","citation_count":37,"is_preprint":false},{"pmid":"38831106","id":"PMC_38831106","title":"The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.","date":"2024","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38831106","citation_count":36,"is_preprint":false},{"pmid":"36081508","id":"PMC_36081508","title":"BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36081508","citation_count":36,"is_preprint":false},{"pmid":"29997289","id":"PMC_29997289","title":"Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells.","date":"2018","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/29997289","citation_count":36,"is_preprint":false},{"pmid":"24084097","id":"PMC_24084097","title":"A novel nanoparticle containing MOG peptide with BTLA induces T cell tolerance and prevents multiple sclerosis.","date":"2013","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24084097","citation_count":35,"is_preprint":false},{"pmid":"29353075","id":"PMC_29353075","title":"BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints.","date":"2018","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/29353075","citation_count":35,"is_preprint":false},{"pmid":"38233898","id":"PMC_38233898","title":"BTLA biology in cancer: from bench discoveries to clinical potentials.","date":"2024","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/38233898","citation_count":34,"is_preprint":false},{"pmid":"24448587","id":"PMC_24448587","title":"An agonistic anti-BTLA mAb (3C10) induced generation of IL-10-dependent regulatory CD4+ T cells and prolongation of murine cardiac allograft.","date":"2014","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/24448587","citation_count":34,"is_preprint":false},{"pmid":"19837478","id":"PMC_19837478","title":"Detection of protein on BTLAlow cells and in vivo antibody-mediated down-modulation of BTLA on lymphoid and myeloid cells of C57BL/6 and BALB/c BTLA allelic variants.","date":"2009","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19837478","citation_count":33,"is_preprint":false},{"pmid":"34217699","id":"PMC_34217699","title":"Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.","date":"2021","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34217699","citation_count":33,"is_preprint":false},{"pmid":"31514450","id":"PMC_31514450","title":"BTLA Expression on Th1, Th2 and Th17 Effector T-Cells of Patients with Systemic Lupus Erythematosus Is Associated with Active Disease.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31514450","citation_count":32,"is_preprint":false},{"pmid":"22637698","id":"PMC_22637698","title":"Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3.","date":"2012","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/22637698","citation_count":32,"is_preprint":false},{"pmid":"26674453","id":"PMC_26674453","title":"Enhanced Innate Inflammation Induced by Anti-BTLA Antibody in Dual Insult Model of Hemorrhagic Shock/Sepsis.","date":"2016","source":"Shock (Augusta, Ga.)","url":"https://pubmed.ncbi.nlm.nih.gov/26674453","citation_count":32,"is_preprint":false},{"pmid":"29518903","id":"PMC_29518903","title":"Downregulation of BTLA on NKT Cells Promotes Tumor Immune Control in a Mouse Model of Mammary Carcinoma.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29518903","citation_count":32,"is_preprint":false},{"pmid":"38418488","id":"PMC_38418488","title":"BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38418488","citation_count":31,"is_preprint":false},{"pmid":"25595777","id":"PMC_25595777","title":"Cutting Edge: the BTLA-HVEM regulatory pathway interferes with protective immunity to intestinal Helminth infection.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25595777","citation_count":31,"is_preprint":false},{"pmid":"18049125","id":"PMC_18049125","title":"Negative and positive co-signaling with anti-BTLA (PJ196) and CTLA4Ig prolongs islet allograft survival.","date":"2007","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/18049125","citation_count":30,"is_preprint":false},{"pmid":"32775467","id":"PMC_32775467","title":"Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.","date":"2020","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/32775467","citation_count":29,"is_preprint":false},{"pmid":"19383625","id":"PMC_19383625","title":"BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice.","date":"2009","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/19383625","citation_count":29,"is_preprint":false},{"pmid":"28594868","id":"PMC_28594868","title":"Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28594868","citation_count":28,"is_preprint":false},{"pmid":"30638415","id":"PMC_30638415","title":"Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndrome.","date":"2019","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/30638415","citation_count":27,"is_preprint":false},{"pmid":"32197584","id":"PMC_32197584","title":"A combination of the activation marker CD86 and the immune checkpoint marker B and T lymphocyte attenuator (BTLA) indicates a putative permissive activation state of B cell subtypes in healthy blood donors independent of age and sex.","date":"2020","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32197584","citation_count":27,"is_preprint":false},{"pmid":"31434927","id":"PMC_31434927","title":"BTLA suppress acute rejection via regulating TCR downstream signals and cytokines production in kidney transplantation and prolonged allografts survival.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31434927","citation_count":26,"is_preprint":false},{"pmid":"32296431","id":"PMC_32296431","title":"BTLA-Expressing Dendritic Cells in Patients With Tuberculosis Exhibit Reduced Production of IL-12/IFN-α and Increased Production of IL-4 and TGF-β, Favoring Th2 and Foxp3+ Treg Polarization.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32296431","citation_count":26,"is_preprint":false},{"pmid":"34709351","id":"PMC_34709351","title":"HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34709351","citation_count":24,"is_preprint":false},{"pmid":"22903545","id":"PMC_22903545","title":"CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells.","date":"2012","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/22903545","citation_count":24,"is_preprint":false},{"pmid":"31963646","id":"PMC_31963646","title":"Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31963646","citation_count":23,"is_preprint":false},{"pmid":"12583894","id":"PMC_12583894","title":"Identification and disruption of btlA, a locus involved in bile tolerance and general stress resistance in Listeria monocytogenes.","date":"2003","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/12583894","citation_count":22,"is_preprint":false},{"pmid":"38387336","id":"PMC_38387336","title":"The BTLA-HVEM complex - The future of cancer immunotherapy.","date":"2024","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38387336","citation_count":22,"is_preprint":false},{"pmid":"17391759","id":"PMC_17391759","title":"IMGT Colliers de Perles and IgSF domain standardization for T cell costimulatory activatory (CD28, ICOS) and inhibitory (CTLA4, PDCD1 and BTLA) receptors.","date":"2007","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17391759","citation_count":22,"is_preprint":false},{"pmid":"27234378","id":"PMC_27234378","title":"Association of 3' nearby gene BTLA polymorphisms with the risk of renal cell carcinoma in the Polish population.","date":"2016","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27234378","citation_count":21,"is_preprint":false},{"pmid":"27717503","id":"PMC_27717503","title":"BTLA-expressing CD11c antigen presenting cells in patients with active tuberculosis exhibit low capacity to stimulate T cell proliferation.","date":"2016","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27717503","citation_count":20,"is_preprint":false},{"pmid":"27743606","id":"PMC_27743606","title":"Hepatic expansion of virus-specific CD8+BTLA+ T cells with regulatory properties in chronic hepatitis B virus infection.","date":"2016","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27743606","citation_count":20,"is_preprint":false},{"pmid":"27933341","id":"PMC_27933341","title":"Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia.","date":"2016","source":"Archivum immunologiae et therapiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/27933341","citation_count":20,"is_preprint":false},{"pmid":"23067542","id":"PMC_23067542","title":"The intrahepatic expression and distribution of BTLA and its ligand HVEM in patients with HBV-related acute-on-chronic liver failure.","date":"2012","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23067542","citation_count":20,"is_preprint":false},{"pmid":"33017473","id":"PMC_33017473","title":"Correlations of the expression of γδ T cells and their co-stimulatory molecules TIGIT, PD-1, ICOS and BTLA with PR and PIBF in the peripheral blood and decidual tissues of women with unexplained recurrent spontaneous abortion.","date":"2020","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33017473","citation_count":20,"is_preprint":false},{"pmid":"33238640","id":"PMC_33238640","title":"Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33238640","citation_count":19,"is_preprint":false},{"pmid":"16426492","id":"PMC_16426492","title":"BTLA, a new inhibitory B7 family receptor with a TNFR family ligand.","date":"2005","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16426492","citation_count":19,"is_preprint":false},{"pmid":"22179929","id":"PMC_22179929","title":"The expression and anatomical distribution of BTLA and its ligand HVEM in rheumatoid synovium.","date":"2012","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/22179929","citation_count":19,"is_preprint":false},{"pmid":"32060969","id":"PMC_32060969","title":"Association between BTLA polymorphisms and susceptibility to esophageal squamous cell carcinoma in the Chinese population.","date":"2020","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/32060969","citation_count":18,"is_preprint":false},{"pmid":"33332777","id":"PMC_33332777","title":"The BTLA and PD-1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells.","date":"2020","source":"Immunity, inflammation and disease","url":"https://pubmed.ncbi.nlm.nih.gov/33332777","citation_count":18,"is_preprint":false},{"pmid":"28393074","id":"PMC_28393074","title":"Adenovirus-Mediated CCR7 and BTLA Overexpression Enhances Immune Tolerance and Migration in Immature Dendritic Cells.","date":"2017","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/28393074","citation_count":18,"is_preprint":false},{"pmid":"33732243","id":"PMC_33732243","title":"Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33732243","citation_count":18,"is_preprint":false},{"pmid":"24321139","id":"PMC_24321139","title":"BTLA as a biomarker and mediator of sepsis-induced immunosuppression.","date":"2013","source":"Critical care (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24321139","citation_count":18,"is_preprint":false},{"pmid":"33968071","id":"PMC_33968071","title":"BTLA Expression and Function Are Impaired on SLE B Cells.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33968071","citation_count":18,"is_preprint":false},{"pmid":"27851922","id":"PMC_27851922","title":"BTLA+ Dendritic Cells: The Regulatory T Cell Force Awakens.","date":"2016","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27851922","citation_count":18,"is_preprint":false},{"pmid":"26277622","id":"PMC_26277622","title":"BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26277622","citation_count":17,"is_preprint":false},{"pmid":"27194787","id":"PMC_27194787","title":"Regulatory T Cell Dysfunction Acquiesces to BTLA+ Regulatory B Cells Subsequent to Oral Intervention in Experimental Autoimmune Encephalomyelitis.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27194787","citation_count":17,"is_preprint":false},{"pmid":"19702559","id":"PMC_19702559","title":"Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.","date":"2009","source":"Recent patents on DNA & gene sequences","url":"https://pubmed.ncbi.nlm.nih.gov/19702559","citation_count":16,"is_preprint":false},{"pmid":"32432730","id":"PMC_32432730","title":"Overexpression of miR-32 inhibits the proliferation and metastasis of ovarian cancer cells by targeting BTLA.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32432730","citation_count":16,"is_preprint":false},{"pmid":"27183113","id":"PMC_27183113","title":"The Expression of BTLA Was Increased and the Expression of HVEM and LIGHT Were Decreased in the T Cells of Patients with Rheumatoid Arthritis [corrected].","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27183113","citation_count":16,"is_preprint":false},{"pmid":"19860669","id":"PMC_19860669","title":"Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targeting.","date":"2009","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19860669","citation_count":15,"is_preprint":false},{"pmid":"31562209","id":"PMC_31562209","title":"BTLA-HVEM Checkpoint Axis Regulates Hepatic Homeostasis and Inflammation in a ConA-Induced Hepatitis Model in Zebrafish.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/31562209","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46858,"output_tokens":5331,"usd":0.11027},"stage2":{"model":"claude-opus-4-6","input_tokens":8937,"output_tokens":4078,"usd":0.219952},"total_usd":0.330222,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"BTLA is an immunoglobulin domain-containing glycoprotein with two immunoreceptor tyrosine-based inhibitory motifs (ITIMs); crosslinking BTLA with antigen receptors induces tyrosine phosphorylation and association with SHP-1 and SHP-2, attenuating IL-2 production. BTLA-deficient T cells show increased proliferation and BTLA-deficient mice have increased antibody responses and enhanced EAE susceptibility.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation assays, BTLA-knockout mouse phenotyping, cytokine production assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — original discovery paper with multiple orthogonal methods, replicated across subsequent studies\",\n      \"pmids\": [\"12796776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structure of the BTLA-HVEM complex at 2.8 Å shows BTLA binds the N-terminal cysteine-rich domain 1 (CRD1) of HVEM, employing a unique binding surface compared with other CD28-like receptors; BTLA adopts an immunoglobulin I-set fold; light scattering demonstrates BTLA ectodomain is monomeric and forms a 1:1 complex with HVEM. Alanine-scanning mutagenesis of HVEM defined critical binding residues. BTLA recognizes the same HVEM surface as herpesvirus glycoprotein D (gD).\",\n      \"method\": \"X-ray crystallography (2.8 Å), light scattering analysis, alanine-scanning mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis validation, foundational structural paper\",\n      \"pmids\": [\"16169851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BTLA cytoplasmic domain contains a third conserved tyrosine motif resembling a Grb-2 recruitment site; phosphopeptide pulldown with mass spectrometry identified Grb-2 and the p85 subunit of PI3K as interacting proteins. Grb-2 binds directly to the phosphotyrosine-containing peptide, whereas p85 recruitment is indirect via its association with Grb-2.\",\n      \"method\": \"Phosphotyrosine peptide pulldown, mass spectrometry, direct binding assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro peptide pulldown with MS identification; single lab, mechanistically defined\",\n      \"pmids\": [\"16725108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Human BTLA is constitutively expressed on most CD4+ and CD8+ T cells and its expression progressively decreases upon T cell activation. Cross-linking BTLA with an agonistic mAb inhibits T cell proliferation and cytokine (IFN-γ and IL-10) production in response to anti-CD3 stimulation, demonstrating a constitutive inhibitory function.\",\n      \"method\": \"Monoclonal antibody cross-linking, T cell proliferation assays, cytokine production assays, flow cytometry\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional loss/gain with defined cellular phenotype, single lab\",\n      \"pmids\": [\"16643847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BTLA interacts with HVEM in cis on the surface of naive T cells, forming a heterodimeric complex that inhibits HVEM-dependent NF-κB activation. The BTLA ectodomain acts as a competitive inhibitor, blocking BTLA and CD160 from binding HVEM in trans and initiating NF-κB activation. LIGHT can bind within the cis-complex but NF-κB activation is attenuated, suggesting BTLA prevents HVEM oligomerization.\",\n      \"method\": \"Cell surface binding assays, NF-κB reporter assays, genetic deletion of BTLA, pharmacologic disruption of cis-complex, T cell reporter systems\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (reporter assays, genetic deletion, pharmacologic disruption), replicated by later study (PMID:36081508)\",\n      \"pmids\": [\"19915044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The HVEM-BTLA inhibitory pathway counter-regulates lymphotoxin receptor (LTβR) signaling to achieve dendritic cell homeostasis. HVEM- and BTLA-deficient mice show overpopulation of CD8α- DC subsets with a growth advantage in competitive bone marrow chimeras. DC expression of both HVEM and BTLA, as well as LTβR, is required for homeostasis.\",\n      \"method\": \"Competitive bone marrow chimeras, knockout mouse analysis, flow cytometry of DC subsets, agonist antibody treatment\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — competitive reconstitution and genetic evidence with defined cellular phenotype\",\n      \"pmids\": [\"18097025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"In a T cell transfer colitis model, HVEM on radioresistant (non-T) cells in recipient mice interacts with BTLA to prevent intestinal inflammation, demonstrating that HVEM expressed by innate immune cells exerts anti-inflammatory effects through BTLA-mediated coinhibitory signaling.\",\n      \"method\": \"Adoptive T cell transfer colitis model, bone marrow chimeras, HVEM/BTLA knockout recipients\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis via bone marrow chimeras, clean KO with defined phenotype\",\n      \"pmids\": [\"18519647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"In GVHD, BTLA serves dual roles: (1) as a receptor that delivers inhibitory signals inhibiting donor anti-host T cell responses when stimulated by an agonistic anti-BTLA antibody, and (2) as a ligand that activates HVEM pro-survival signaling in donor T cells independently of its intracellular signaling domain, as shown by a BTLA cytoplasmic-truncation mutant restoring survival of BTLA-deficient T cells.\",\n      \"method\": \"Agonistic anti-BTLA antibody, BTLA intracellular domain-deletion mutant, GVHD mouse model, survival assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis of signaling domain combined with in vivo disease model establishes bidirectional mechanism\",\n      \"pmids\": [\"21220749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BTLA expression on CD8α+ dendritic cells functions as a trans-activating ligand delivering positive co-signals through HVEM expressed on CD8+ T cells, promoting effector CD8 T cell survival and memory formation in vaccinia virus infection. Mixed adoptive transfer experiments demonstrate the cell-type requirement.\",\n      \"method\": \"Mixed adoptive transfer, HVEM/BTLA knockout mouse models, viral infection model, memory T cell quantification\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with mixed adoptive transfer, two independent PMID studies converging on same mechanism\",\n      \"pmids\": [\"24205056\", \"24205057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In γδ T cells, BTLA expression is regulated by the transcription factor RORγt (which represses Btla transcription via its AF-2 domain) and IL-7 (which increases BTLA surface levels). BTLA limits γδ T cell numbers by restricting IL-7-responsiveness and negatively regulates IL-17 and TNF production in CD27- γδ T cells.\",\n      \"method\": \"BTLA-deficient mice, RORγt AF-2 domain mutants, IL-7 stimulation assays, dermatitis mouse model, BTLA agonism\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic tools and domain mutants with in vivo phenotype readout\",\n      \"pmids\": [\"24315996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BTLA+DEC205+CD8+CD11c+ dendritic cells efficiently induce extrathymic regulatory T (Treg) cell differentiation. Engagement of HVEM on T cells by BTLA on DCs promotes Foxp3 expression via upregulation of CD5, which enables T cells to resist inhibition of Foxp3 by effector-differentiating cytokines.\",\n      \"method\": \"DC subset purification and T cell co-culture, BTLA/HVEM knockout mice, Foxp3 and CD5 expression analysis, in vivo tolerance models\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway dissection with genetic tools and defined molecular intermediates\",\n      \"pmids\": [\"27793593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BTLA function is impaired in lupus CD4+ T cells due to defective recruitment of BTLA to the immunological synapse following T cell stimulation; this defect can be corrected by restoring intracellular lipid metabolism and trafficking in SLE T cells.\",\n      \"method\": \"Immunological synapse imaging, BTLA localization assays, lipid metabolism rescue experiments, functional T cell assays\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment tied to functional consequence, single lab\",\n      \"pmids\": [\"29997289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Quantitative interactomics in primary T cells shows BTLA predominantly recruits SHP-1 (and to a lesser extent SHP-2) to form its coinhibitory signalosome, in contrast to PD-1 which predominantly recruits SHP-2. Both BTLA-SHP-1 and PD-1-SHP-2 complexes equally dampen TCR and CD28 signaling pathways.\",\n      \"method\": \"Quantitative mass spectrometry interactomics (AP-MS) in primary T cells, T cell-APC interface analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — quantitative interactomics in primary cells with rigorous controls, confirmed by independent study\",\n      \"pmids\": [\"31189114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BTLA signaling into T cells through SHP1 reduces TCR signaling and preformed CD40 ligand mobilization to the immunological synapse, diminishing T cell help delivered to germinal center B cells. T cell-specific BTLA deficiency cooperates with B cell Bcl-2 overexpression to drive GC B cell outgrowth, establishing BTLA as a cell-extrinsic suppressor of GC B cell lymphomagenesis.\",\n      \"method\": \"BTLA conditional knockout mice, immunological synapse imaging, TCR signaling assays, CD40L mobilization assays, GC response analysis, Bcl-2 transgenic cooperation\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods linking molecular mechanism to in vivo disease phenotype\",\n      \"pmids\": [\"31204070\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BTLA preferentially recruits SHP-1 over SHP-2 to suppress T cell signaling more efficiently than PD-1. In SHP1/SHP2 double-deficient primary T cells, both PD-1 and BTLA still potently inhibit proliferation and cytokine production, demonstrating that both receptors can also suppress T cell signaling through a mechanism independent of SHP1 and SHP2.\",\n      \"method\": \"SHP1/SHP2 double-deficient primary T cells, reconstitution assays, T cell proliferation and cytokine assays, phosphatase recruitment comparison\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic double-knockout combined with functional assays, two independent groups reaching similar conclusions\",\n      \"pmids\": [\"32437509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Crystal structures reveal HVEM simultaneously interacts with LIGHT via one surface and with BTLA/CD160 via the distinct CRD1 surface, forming a ternary complex. Mouse HVEM knockin mutants selectively recognizing either TNF or Ig ligands demonstrate selective in vivo functions: LIGHT drives clearance of intestinal bacteria, while Ig ligands (BTLA/CD160) ameliorate liver inflammation.\",\n      \"method\": \"X-ray crystallography (human HVEM-LIGHT-CD160 ternary complex), site-directed mutagenesis, knockin mouse models, in vivo infection and inflammation models\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus knockin mutagenesis in vivo, rigorous functional dissection\",\n      \"pmids\": [\"34709351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In the BTLA-HVEM cis-complex on T cells, BTLA-mediated inhibition is not impaired; co-expression with LIGHT or CD160 (but not BTLA) induces strong constitutive HVEM signaling. BTLA inhibition is dominant in the heterodimeric cis-complex, and HVEM antibodies can simultaneously act as checkpoint inhibitors and costimulation agonists.\",\n      \"method\": \"T cell reporter systems, primary human T cell stimulation assays, co-expression studies with HVEM ligands\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter systems plus primary T cells, single lab\",\n      \"pmids\": [\"36081508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BTLA inhibits CAR T cells via recruitment of tyrosine phosphatases SHP-1 and SHP-2 upon trans engagement with HVEM on regulatory T cells in the tumor microenvironment. Deletion of BTLA in CAR T cells improves tumor control and persistence in lymphoma and solid tumor models.\",\n      \"method\": \"BTLA knockout CAR T cells, phosphatase recruitment assays, mouse lymphoma and solid tumor models, CAR T cell functional assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic deletion with defined molecular mechanism and in vivo tumor models\",\n      \"pmids\": [\"38831106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BTLA levels are upregulated on CD4+ T cells from HBV-ACLF patients by IL-6 and TNF signaling pathways. Antibody crosslinking of BTLA activates the PI3K-Akt pathway to inhibit activation, proliferation, and cytokine production of CD4+ T cells while promoting apoptosis. BTLA knockdown promotes CD4+ T cell activation and proliferation. BTLA-/- ACLF mice show increased cytokine secretion and reduced mortality and bacterial burden.\",\n      \"method\": \"BTLA antibody crosslinking, PI3K-Akt pathway activation assays, BTLA knockdown, BTLA-knockout ACLF mouse model, anti-BTLA neutralizing antibody treatment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (antibody crosslinking, knockdown, knockout mice) with defined molecular pathway\",\n      \"pmids\": [\"38418488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The Grb2-binding motif of BTLA mediates a costimulatory function in CD8+ T cells by enhancing IL-2 secretion and Src activation after TCR stimulation. BTLA+ CD8+ TILs show improved survival following tumor target killing and enhanced serial killing capacity; BTLA- TILs have impaired recall responses to vaccination.\",\n      \"method\": \"BTLA signaling motif mutants (ITIM/ITSM vs Grb2 motif), RPPA signaling arrays, antigen-specific vaccination models, adoptive transfer with TCR-transgenic T cells, PDX tumor models\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain mutagenesis with multiple functional readouts, single lab\",\n      \"pmids\": [\"28754817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BTLA expression in macrophages promotes the pathogenesis of virus-induced fulminant hepatitis by enhancing macrophage viability. BTLA-/- mice show rapid TRAIL-dependent apoptosis of MHV-3-infected macrophages, resulting in reduced TNFα, FGL2, viral titers, and improved survival. Adoptive transfer of macrophages to BTLA-/- mice restores sensitivity.\",\n      \"method\": \"BTLA-knockout mouse model, MHV-3 infection, macrophage adoptive transfer, BTLA blockade, TRAIL-dependent apoptosis assays, cytokine measurements\",\n      \"journal\": \"Gut\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with mechanistic rescue via adoptive transfer, multiple orthogonal validations\",\n      \"pmids\": [\"22637698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BTLA interaction with HVEM inhibits CpG (TLR9)-mediated B cell functions including proliferation, cytokine production, and upregulation of co-stimulatory molecules; this inhibition is reversed by blocking BTLA/HVEM interactions. Chemokine secretion (IL-8 and MIP1β) is not affected, showing BTLA-mediated inhibition is selective for certain B cell functions.\",\n      \"method\": \"CpG stimulation of human B cells, BTLA/HVEM blocking antibodies, functional assays for proliferation and cytokine production\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional blocking with defined selectivity, single lab\",\n      \"pmids\": [\"22903545\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BTLA is an ITIM-containing immunoglobulin superfamily inhibitory receptor that, upon tyrosine phosphorylation triggered by antigen receptor crosslinking or HVEM engagement in trans, recruits predominantly SHP-1 (and to a lesser extent SHP-2) to suppress TCR/CD28 and BCR signaling, inhibit IL-2 production, and restrain T and B cell proliferation; BTLA also forms a cis-heterodimeric complex with its ligand HVEM on naive T cells that blocks HVEM costimulation and maintains T cell quiescence, while BTLA itself can act as a trans-activating ligand for HVEM on adjacent cells to deliver NF-κB-dependent pro-survival and memory-promoting signals, and its Grb2-binding motif additionally mediates a costimulatory function enhancing IL-2 and Src activation in CD8+ T cells.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BTLA is an immunoglobulin superfamily coinhibitory receptor that functions as a central regulator of adaptive and innate immune cell activation, restraining T cell, B cell, dendritic cell, and macrophage responses through both receptor-intrinsic inhibitory signaling and bidirectional communication with its ligand HVEM. Upon engagement by HVEM in trans or crosslinking with the antigen receptor, BTLA undergoes tyrosine phosphorylation at its ITIM/ITSM motifs and preferentially recruits the phosphatase SHP-1 (and to a lesser extent SHP-2) to suppress TCR, CD28, and BCR signaling, thereby inhibiting proliferation, cytokine production, and CD40L mobilization to the immunological synapse [PMID:12796776, PMID:31189114, PMID:31204070]; an additional SHP-1/SHP-2-independent inhibitory mechanism also operates [PMID:32437509]. BTLA simultaneously acts as a ligand for HVEM: on naive T cells it forms a cis-heterodimeric complex with HVEM that blocks HVEM costimulation and maintains quiescence [PMID:19915044, PMID:36081508], while in trans BTLA on dendritic cells delivers NF-κB-dependent pro-survival signals through HVEM on T cells, promoting regulatory T cell differentiation, effector CD8+ T cell memory, and CD5-dependent Foxp3 induction [PMID:24205056, PMID:27793593, PMID:21220749]. A third tyrosine motif in the BTLA cytoplasmic tail recruits Grb2 and mediates a costimulatory function in CD8+ T cells that enhances IL-2 production and Src activation [PMID:16725108, PMID:28754817].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Identification of BTLA as a novel ITIM-bearing inhibitory receptor resolved the question of whether additional immunoglobulin-family coinhibitory molecules beyond CTLA-4 and PD-1 existed, establishing that BTLA recruits SHP-1 and SHP-2 upon phosphorylation to attenuate T cell activation and antibody responses.\",\n      \"evidence\": \"BTLA-knockout mice, co-immunoprecipitation, IL-2 production assays, EAE susceptibility model\",\n      \"pmids\": [\"12796776\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand for BTLA unknown at this stage\", \"Relative contribution of SHP-1 vs SHP-2 not resolved\", \"Mechanism of action in B cells not directly tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Structural determination of the BTLA–HVEM complex revealed that an Ig-superfamily receptor binds a TNF receptor superfamily member — an unprecedented cross-family interaction — establishing the molecular basis for BTLA engagement and showing BTLA binds CRD1 of HVEM as a 1:1 monomer.\",\n      \"evidence\": \"X-ray crystallography at 2.8 Å, light scattering, alanine-scanning mutagenesis of HVEM\",\n      \"pmids\": [\"16169851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BTLA and LIGHT can simultaneously engage HVEM not resolved\", \"In vivo significance of identified contact residues untested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Discovery of a Grb2-binding tyrosine motif in BTLA's cytoplasmic tail, beyond the canonical ITIMs, revealed an unexpected signaling complexity suggesting BTLA could transmit both inhibitory and costimulatory signals depending on context.\",\n      \"evidence\": \"Phosphopeptide pulldown with mass spectrometry, direct binding assays identifying Grb2 and indirect PI3K p85 recruitment\",\n      \"pmids\": [\"16725108\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of Grb2 recruitment in T cells not yet demonstrated\", \"Whether Grb2 motif operates independently of ITIMs unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"In vivo studies using bone marrow chimeras and adoptive transfer colitis models established that the BTLA–HVEM axis operates bidirectionally in distinct immune compartments — restraining T cell-mediated intestinal inflammation and controlling dendritic cell homeostasis by counter-regulating LTβR signaling.\",\n      \"evidence\": \"Competitive bone marrow chimeras, HVEM/BTLA-knockout recipients, adoptive T cell transfer colitis model\",\n      \"pmids\": [\"18097025\", \"18519647\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking BTLA to LTβR counter-regulation in DCs not defined\", \"Whether BTLA acts as receptor or ligand on DCs in homeostasis unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery of the BTLA–HVEM cis-complex on naive T cells revealed a cell-autonomous mechanism by which BTLA blocks HVEM costimulation and maintains T cell quiescence, answering how HVEM can be silenced despite constitutive expression on resting cells.\",\n      \"evidence\": \"Cell surface binding assays, NF-κB reporter systems, genetic deletion of BTLA, pharmacologic disruption\",\n      \"pmids\": [\"19915044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the cis-complex is disrupted during activation not fully resolved\", \"Whether cis-complex affects BTLA's own inhibitory signaling unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Using a BTLA cytoplasmic-truncation mutant in GVHD, BTLA was shown to function as a trans-activating ligand for HVEM independently of its own intracellular signaling, establishing a bidirectional signaling paradigm in which BTLA delivers pro-survival signals to adjacent HVEM-expressing T cells.\",\n      \"evidence\": \"BTLA intracellular domain-deletion mutant, agonistic anti-BTLA antibody, GVHD mouse model\",\n      \"pmids\": [\"21220749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ligand function requires specific BTLA ectodomain residues not mapped\", \"Downstream NF-κB-dependent targets in HVEM-expressing cells not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"BTLA's functional scope was extended beyond lymphocytes: in macrophages BTLA promotes survival during viral hepatitis (its absence causes TRAIL-dependent apoptosis), and in B cells BTLA–HVEM interaction selectively inhibits TLR9-driven proliferation and cytokine production without affecting chemokine secretion.\",\n      \"evidence\": \"BTLA-KO mice with MHV-3 infection and macrophage adoptive transfer; CpG-stimulated human B cells with BTLA/HVEM blocking antibodies\",\n      \"pmids\": [\"22637698\", \"22903545\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BTLA selectively inhibits certain TLR9-driven outputs but not others is unknown\", \"Whether BTLA pro-survival signaling in macrophages is SHP-dependent or HVEM-dependent unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Mechanistic studies revealed that BTLA on CD8α+ DCs serves as a trans-ligand for HVEM on CD8+ T cells to promote effector survival and memory formation, and that RORγt transcriptionally represses Btla to license γδ T cell expansion and IL-17 production, establishing BTLA as a transcriptionally regulated checkpoint in innate-like lymphocytes.\",\n      \"evidence\": \"Mixed adoptive transfer with HVEM/BTLA-KO mice in vaccinia infection; RORγt AF-2 domain mutants, BTLA-deficient γδ T cell analysis in dermatitis model\",\n      \"pmids\": [\"24205056\", \"24205057\", \"24315996\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BTLA ligand function on DCs requires phosphorylation of BTLA not tested\", \"How RORγt AF-2 domain mediates Btla repression at the chromatin level undefined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"The trans-ligand function of BTLA on DCs was linked to extrathymic Treg differentiation: BTLA engagement of HVEM on T cells upregulates CD5, which protects Foxp3 induction from suppression by effector-differentiating cytokines, placing BTLA at the nexus of peripheral tolerance.\",\n      \"evidence\": \"DC subset purification and T cell co-culture, BTLA/HVEM-KO mice, Foxp3 and CD5 expression analysis, in vivo tolerance models\",\n      \"pmids\": [\"27793593\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediates between HVEM engagement and CD5 upregulation not identified\", \"Whether this mechanism operates in human Treg induction untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The Grb2-binding motif of BTLA was functionally dissected in CD8+ T cells, revealing it delivers a costimulatory signal that enhances IL-2 secretion and Src activation, with BTLA+ TILs showing improved serial killing capacity — resolving how the same receptor can provide both inhibitory and costimulatory inputs.\",\n      \"evidence\": \"BTLA signaling motif mutants (ITIM/ITSM vs Grb2), RPPA signaling arrays, antigen-specific vaccination models, PDX tumor models\",\n      \"pmids\": [\"28754817\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How Grb2-motif costimulation integrates with ITIM-mediated inhibition in the same cell is not quantitatively modeled\", \"Whether the costimulatory function is relevant in CD4+ T cells or other lineages unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Quantitative interactomics in primary T cells definitively established SHP-1 as the dominant BTLA phosphatase partner (distinguishing it from PD-1's SHP-2 preference), and conditional BTLA deletion in T cells showed that BTLA suppresses CD40L delivery to the immunological synapse, restraining germinal center B cell expansion and lymphomagenesis.\",\n      \"evidence\": \"AP-MS interactomics in primary T cells; conditional KO mice with Bcl-2 transgenic cooperation, immunological synapse imaging\",\n      \"pmids\": [\"31189114\", \"31204070\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SHP-1 and SHP-2 have non-redundant substrates downstream of BTLA not resolved\", \"The SHP-independent inhibitory mechanism remains molecularly undefined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Generation of SHP-1/SHP-2 double-deficient T cells revealed that BTLA retains potent inhibitory function even without both phosphatases, proving the existence of a SHP-independent signaling arm whose molecular basis remains unknown.\",\n      \"evidence\": \"SHP1/SHP2 double-deficient primary T cells, reconstitution assays, proliferation and cytokine assays\",\n      \"pmids\": [\"32437509\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the SHP-independent effector(s) is unknown\", \"Whether this mechanism operates in non-T cells not addressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Crystal structures of the ternary HVEM–LIGHT–CD160/BTLA complex showed that HVEM can simultaneously engage TNF-family and Ig-family ligands on distinct surfaces, and knockin mouse mutants selectively disrupting each interface demonstrated that Ig ligands (BTLA/CD160) specifically ameliorate liver inflammation while LIGHT controls bacterial clearance.\",\n      \"evidence\": \"X-ray crystallography of human ternary complex, site-directed mutagenesis, HVEM knockin mouse models, in vivo infection and inflammation\",\n      \"pmids\": [\"34709351\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BTLA and CD160 have non-redundant roles in the Ig-ligand arm not separated\", \"Structural basis for how the cis-complex is regulated during T cell activation unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Reporter and primary T cell assays clarified that within the cis-complex, BTLA's inhibitory function remains fully active and dominant, while HVEM costimulatory signaling is specifically induced by CD160 or LIGHT but not BTLA in cis, resolving how cis and trans signaling modes are segregated.\",\n      \"evidence\": \"T cell reporter systems, primary human T cell stimulation, co-expression studies with HVEM ligands\",\n      \"pmids\": [\"36081508\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How BTLA cis-inhibition is overridden during strong activation signals unknown\", \"Translation to in vivo settings not yet demonstrated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Translational studies demonstrated that BTLA-mediated inhibition is a functional checkpoint in CAR T cell therapy (where HVEM on Tregs engages BTLA to suppress anti-tumor activity) and in hepatitis-associated acute-on-chronic liver failure (where IL-6/TNF upregulate BTLA on CD4+ T cells to activate PI3K-Akt-mediated suppression), establishing BTLA as a therapeutic target in both cancer and inflammatory liver disease.\",\n      \"evidence\": \"BTLA-KO CAR T cells in lymphoma/solid tumor models; BTLA crosslinking with PI3K-Akt pathway analysis, BTLA-KO ACLF mouse model\",\n      \"pmids\": [\"38831106\", \"38418488\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BTLA deletion in CAR T cells affects long-term persistence and exhaustion not fully assessed\", \"The PI3K-Akt pathway activation by BTLA crosslinking in hepatitis appears paradoxical relative to its inhibitory function and requires mechanistic clarification\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular identity of the SHP-1/SHP-2-independent inhibitory effector downstream of BTLA remains unknown, and how the Grb2-mediated costimulatory and ITIM-mediated inhibitory signals are integrated within the same cell to determine net signaling outcome is unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SHP-independent effector unidentified\", \"Quantitative model of costimulatory vs inhibitory signal integration lacking\", \"Structural basis for cis-to-trans complex transition during T cell activation undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 12, 14, 17]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 2, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 3, 4, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 3, 6, 9, 13, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 7, 10, 18]}\n    ],\n    \"complexes\": [\n      \"BTLA-HVEM cis-complex\",\n      \"BTLA-SHP-1 signalosome\"\n    ],\n    \"partners\": [\n      \"TNFRSF14\",\n      \"PTPN6\",\n      \"PTPN11\",\n      \"GRB2\",\n      \"CD160\",\n      \"TNFSF14\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}